Skip to main content
OpenTrials
Completed

NCT Number: NCT05817188

Medication Repurposing to Stop Cognitive Decline in Dementia

Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. Many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia.

Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has >100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination-MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. The investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. The investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Karolinska Institutet

Stockholm, 17177, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients with dementia registered in SveDem.

Exclusion criteria

Lack of Swedish personal identification number or coordination number.

Treatment and study plan

No intervention

Other

No intervention was applied

Primary outcomes

  1. Cognitive decline

    Time frame: Through study completion, at least 1 year

    The data on cognitive decline will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.

Secondary outcomes

  1. Rate of nursing home placement

    Time frame: Through study completion, at least 1 year

    Data will be obtained from the social services registry.

  2. Mortality

    Time frame: Through study completion, at least 1 year

    Data about date and cause(s) of death will be collected from The Cause of Death Register.

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • KTH Royal Institute of Technology
  • Region Stockholm

Registry information

Official study title

Translational Identification of Medication Repurposing Candidates to Slow Cognitive Decline in Dementia

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Apr 18, 2023
Registry last updated
May 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.